ビットカジノ 入金方法 Activities,In
- December 28, 2016
- Change in Consolidated Subsidiaries (Share Transfer)
- November 18, 2016
- Release of DESALEX Tablets 5mg ビットカジノreatment of allergic diseases
- November 7, 2016
- Consolidated Financial Results (ビットカジノhe second Quarter Ended Sep 30,2016)- Supplementary Information
- November 7, 2016
- Summary of Consolidated Financial Results (ビットカジノhe second Quarter Ended Sep 30,2016)［Japanese Standard］
- October 17, 2016
- Release of Alcohol free hand-sanitizer Noahtect
- October 4, 2016
- LAUNCH OF URITOS TABLETS FOR OVERACTIVE BLADDER IN THAILAND
- September 28, 2016
- MSD K.K. receives manufacturing and marketing approval for DESALEX Tablets 5mg ビットカジノreatment of allergic diseases
- September 15, 2016
- MSD and Kyorin Sign Agreement on Co-Promotion of Therapeutic Agent for Allergic Rhinitis, NASONEX Nasal
- September 1, 2016
- Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
- July 29, 2016
- Consolidated Financial Results (ビットカジノhe First Quarter Ended June 30,2016)- Supplementary Information
- July 29, 2016
- Summary of Consolidated Financial Results (ビットカジノhe First Quarter Ended June 30, 2016) [Japanese Standard]
- June 20, 2016
- NHI Drug Price Listing and Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
- May 25, 2016
- MSD's investigational antiallergic agent desloratadine to be exclusively marketed by Kyorin
- May 12, 2016
- Supplementary information (May 12, 2016)
- March 30, 2016
- Kyorin and Kissei signed an Agreement for Co-Development and Co-Marketing of KRP-114V
- February 3, 2016
- Summary of Consolidated Financial Results (ビットカジノhe third Quarter Ended Dec 31,2015)［Japanese Standard］
- February 3, 2016
- Consolidated Financial Results (ビットカジノhe third Quarter Ended Dec 31,2015)- Supplementary Information
- February 3, 2016
- Revision of Consolidated Financial Forecasts
- February 3, 2016
- Termination of License Concerning COPD Therapeutic Drug KRP-AB1102F
- 1